Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    

MEDIVATION INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Medivation Inc : MDVN, OXBT, PTIE and SYMM added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/23/2013 | 03:30pm CEST

New York, NY - (ACCESSWIRE) - 10/23/2013 - Equity Profile Report initiates its NASDAQ Gainers Watch List adding Medivation, Inc. (NASDAQ:MDVN), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Pain Therapeutics Inc. (NASDAQ:PTIE), and Symmetricom Inc. (NASDAQ:SYMM)

Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses on development and commercialization of novel therapies to treat serious diseases in the United States is currently up (+8.17%) on 4,286,602 shares traded after Medivation and Astellas Announced the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer. Medivation, Inc. (NASDAQ:MDVN) is currently up (+28.65%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Medivation, Inc. (NASDAQ:MDVN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MDVN&SubId=AW

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+30.00%) on 6,172,456 shares traded after Oxygen Biotherapeutics Signed Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+52.94%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OXBT&SubId=AW

Pain Therapeutics Inc. (NASDAQ:PTIE) a biopharmaceutical company that develops novel drugs is currently up (+16.00%) on 2,154,392 shares traded after Pain Therapeutics Reported that Pfizer Elects to Continue Development of REMOXY. Pain Therapeutics Inc. (NASDAQ:PTIE) is currently up (+75.35%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Pain Therapeutics Inc. (NASDAQ:PTIE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PTIE&SubId=AW

Symmetricom Inc. (NASDAQ:SYMM) a company that provides timekeeping technologies, instruments, and solutions worldwide is currently up (+51.15%) on 16,220,860 shares traded after Symmetricom Reported its First Quarter Fiscal Year 2014 Financial Results. Symmetricom Inc. (NASDAQ:SYMM) is currently up (+66.13%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Symmetricom Inc. (NASDAQ:SYMM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SYMM&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
2016Drugmaker Sanofi hungry for deals after earnings beat
RE
2016MEDIVATION : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼..
BU
2016Pfizer Throws Out Plan to Split Into Two Companies
DJ
2016FARUQI & FARUQI, LLP : Announces Filing of a Class Action Lawsuit Against Mediva..
PR
2016EXCLUSIVE - GW PHARMACEUTICALS HIRES : sources
RE
2016MEDIVATION SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation..
PR
2016Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation,..
BU
2016Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale o..
BU
2016SHAREHOLDER UPDATE : Brodsky & Smith, LLC Announces an Investigation of The Boar..
PR
2016Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale o..
BU
More news
News from SeekingAlpha
2017Vantage Point - Are Charities The Best Way To Pay For Costly Drugs? 
2017Axovant Sciences announces appointment of Dr. David Hung as CEO and expansion.. 
2017BIOTECH FORUM DAILY DIGEST : Biotech Closes Above Resistance Levels. Icahn Getti.. 
2017BIOTECH FORUM DAILY DIGEST : Buyout Rumors On The Rise; Aratana Therapeutics' De.. 
2017Pfizer May Be Another IBM 
Managers
NameTitle
Elizabeth Barrett Chief Executive Officer
Kim D. Blickenstaff Chairman
Anne Bowdidge Senior Director-Investor Relations
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC0
GILEAD SCIENCES-5.60%88 639
VERTEX PHARMACEUTICALS4.75%40 003
REGENERON PHARMACEUTICALS-21.45%31 288
GENMAB19.78%11 817
BEIGENE LTD (ADR)97.99%10 337